A 2-part Phase 1b Clinical Trial to Evaluate CRB-913 in People with Obesity
Phase 1
252
about 8 months
18–75
15 sites in AL, AZ, CA +7
About this study
This trial is testing the safety of a new drug called CRB-913. It has two parts: Part 1 measures how the drug affects people's bodies, and Part 2 compares CRB-913 to a placebo (inactive pill) over 12 weeks to see if it helps with weight loss and blood levels of the drug.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take CRB-913
- 2.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Part 1: To evaluate the PK of a single dose of CRB-913 - Cmax, Part 1: To evaluate the PK of a single dose of CRB-913 - T1/2, Part 1: To evaluate the PK of a single dose of CRB-913 - Tmax, Part 2: To evaluate the safety of CRB-913 - TEAE
Secondary: Part 1: To evaluate the safety of a single dose of CRB-913 - TEAE, Part 2: To evaluate the PK of CRB-913 - Cmax, Part 2: To evaluate the PK of CRB-913 - Tmax